Santen Pharmaceutical Co., Ltd. (TYO:4536)
1,915.50
+27.00 (1.43%)
May 29, 2026, 3:30 PM JST
Santen Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 37,561 | 35,853 | 26,703 | -14,983 | 27,189 |
Depreciation & Amortization | 18,358 | 17,948 | 18,178 | 17,249 | 17,055 |
Loss (Gain) From Sale of Assets | 3,841 | 1,302 | 7,779 | 34,560 | 232 |
Loss (Gain) on Equity Investments | - | 685 | 7,575 | 2,362 | 1,604 |
Other Operating Activities | -7,642 | -12,288 | -12,287 | -7,990 | -10,318 |
Change in Accounts Receivable | 2,669 | 18,512 | 18,384 | -6,443 | -1,965 |
Change in Inventory | -10,025 | -8,381 | -1,369 | -1,144 | 5,383 |
Change in Accounts Payable | -4,024 | -9,586 | -2,369 | 1,690 | 2,748 |
Change in Other Net Operating Assets | 2,762 | 16,883 | 10,055 | 11,846 | 4,115 |
Operating Cash Flow | 43,500 | 60,928 | 72,649 | 37,147 | 46,043 |
Operating Cash Flow Growth | -28.60% | -16.13% | 95.57% | -19.32% | 18.64% |
Capital Expenditures | -6,844 | -6,662 | -9,319 | -17,277 | -17,344 |
Cash Acquisitions | - | - | -207 | -3,470 | -2,969 |
Sale (Purchase) of Intangibles | -6,469 | -4,357 | -572 | -7,311 | -18,497 |
Investment in Securities | 360 | 3,152 | 3,826 | 1,560 | 2,803 |
Other Investing Activities | -21 | -356 | 127 | -279 | 838 |
Investing Cash Flow | -12,974 | -8,223 | -6,145 | -26,777 | -35,169 |
Short-Term Debt Issued | - | - | - | - | 10,460 |
Long-Term Debt Issued | - | - | - | 15,639 | 10,000 |
Total Debt Issued | - | - | - | 15,639 | 20,460 |
Short-Term Debt Repaid | - | - | - | -11,278 | - |
Long-Term Debt Repaid | - | -158 | -2,112 | - | - |
Total Debt Repaid | - | -158 | -2,112 | -11,278 | - |
Net Debt Issued (Repaid) | - | -158 | -2,112 | 4,361 | 20,460 |
Repurchase of Common Stock | -32,797 | -37,883 | -16,962 | -26,007 | - |
Common Dividends Paid | -12,642 | -12,111 | -11,881 | -12,607 | -11,994 |
Other Financing Activities | -3,909 | -3,155 | -3,076 | -2,967 | -2,909 |
Financing Cash Flow | -49,348 | -53,307 | -34,031 | -37,220 | 5,557 |
Foreign Exchange Rate Adjustments | 6,700 | -983 | 4,206 | 1,739 | 3,694 |
Miscellaneous Cash Flow Adjustments | - | - | - | - | 1 |
Net Cash Flow | -12,122 | -1,585 | 36,679 | -25,111 | 20,126 |
Free Cash Flow | 36,656 | 54,266 | 63,330 | 19,870 | 28,699 |
Free Cash Flow Growth | -32.45% | -14.31% | 218.72% | -30.76% | -17.22% |
Free Cash Flow Margin | 12.57% | 18.09% | 20.97% | 7.12% | 10.78% |
Free Cash Flow Per Share | 111.63 | 155.18 | 172.03 | 51.29 | 71.67 |
Cash Interest Paid | 1,263 | 1,093 | 830 | 465 | 240 |
Cash Income Tax Paid | 7,437 | 12,188 | 12,108 | 7,818 | 10,246 |
Levered Free Cash Flow | 21,413 | 40,191 | 57,849 | 10,007 | 6,630 |
Unlevered Free Cash Flow | 22,659 | 40,867 | 58,369 | 10,305 | 6,786 |
Change in Working Capital | -8,618 | 17,428 | 24,701 | 5,949 | 10,281 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.